The National Health Surveillance Agency (Anvisa) officially announced a series of preventive measures against the sale of Cannabis products this Wednesday (11/19/2025). The Resolution-RE No. 4,641, published in the Official Gazette, determines the suspension of advertising of medicines offered by various companies.

The resolution imposed specific sanctions on Ease Labs Pharmaceutical Laboratory Ltd. The suspension of the advertisement of the items "Cannabis Sativa Extract" and "Cannabidiol Ease Labs" on websites and printed materials was determined. The company comments that it has information that the mentioned material was active before 2025, "disconnected from the practices and guidelines currently adopted," states in a note.

The regulatory agency pointed out the non-compliance with article 12 of RDC 327/2019. This standard, which regulates the Sanitary Authorization for Cannabis products, prohibits advertising to the general public and restricts disclosure only to the medical and pharmaceutical class.

"It is important to clarify that the publication has no relationship, not even questioning, regarding the quality and safety of its products, and the pointing is restricted exclusively to specific points of communication materials," said Ease Labs in a note.

Official Note - Ease Labs is aware of the publication in the Official Gazette regarding an alleged failure to comply with advertising restrictions.

The company was signaled that the object that motivated the publication corresponds to material that was active before February 2025, therefore, disconnected from the practices and guidelines currently adopted.

However, upon learning of the publication, the company promptly requested Anvisa the full copy of the process and, at the moment, the company awaits the receipt of this documentation for a more detailed analysis.

The company reaffirms its permanent commitment to compliance with regulatory standards.

It is important to clarify that the publication has no relationship, not even questioning, regarding the quality and safety of its products, and the pointing is restricted exclusively to specific points of communication materials.

Ease Labs reaffirms its commitment to transparency and regulatory compliance in all its operations.

Another decision by Anvisa: Sales platforms receive restrictions

Finally, the agency extended the prohibitions to online sales platforms, such as the sites "Simple Cannabis" and "Formula Cannabis". The inspection identified the advertisement of imported and national Cannabis products without regularization, which contradicts the legislation for import and trade in the sector.

Simple Cannabis, in a note, stated that it has already requested the immediate removal of the content pointed out, exactly as per Anvisa's guidelines. "We will continue to collaborate with the Agency to ensure total regulatory compliance and maintain our commitment to responsible information and safe access to medicinal cannabis in Brazil."

Official Note – Simple Cannabis reinforces that it fully respects Anvisa and recognizes its importance as the regulatory authority of the sector.

As soon as we were notified, we requested the immediate removal of the content pointed out, exactly as per the Agency's guidelines.

We are open to establishing a transparent dialogue with Anvisa to understand in detail what points were considered inadequate, since we do not display photos of products on our site – only illustrative images to facilitate customer understanding, a common practice throughout the market.

We will continue to collaborate with the Agency to ensure total regulatory compliance and maintain our commitment to responsible information and safe access to medicinal cannabis in Brazil.

Contacted by Sechat's report, Formula Cannabis has not yet responded as of the publication date.